ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

CYPH // Cypherpunk Technologies Inc.

DES <GO> NASDAQ RQD COCKPIT → CIK 0001509745 ↗
Health Care • Biotechnology: Pharmaceutical Preparations
$2.98 ▼ -0.33 (-9.97%)
MKT CAP: $356.7M • VOL: 14.41M
CYPH // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE
▲ UPGRADE // D- (RQD 40) -> D (RQD 45)
ROARABLE D
RQD CONFIDENCE
45 / 100 +5D
5 X 20-PT QUANT PILLARS
E 0 D 35 C 59 B 70 A 86+
Roarable Sell — Underperform / Distribution Warning
01 MASSIVE / SEC XBRL
Forensic Fundamentals
4 / 20
CRITICAL
FCF +27.2% vs NI +107.4% • ROIC-WACC -31.9% • Z 3.2
02 INSTITUTIONAL TAPE & TREND
Whale & Options Flow
17 / 20
STRONG
52W RANGE 77% • VS 200D +156.6% • RSI 56
03 SEC XBRL CAPITAL ALLOCATION
Insider & Capital Conviction
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
04 FRED 90D r-MATRIX
Macro Regime Fit
11 / 20
NEUTRAL
NEUTRAL • r(10Y)=-0.07 (+23bp) • r(OAS)=-0.10
05 10-K REDLINE AUDIT
Forensic 10-K Risk
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
ALERT

Why did CYPH's Insider & Capital Conviction & Forensic 10-K Risk sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever CYPH is Upgraded or Downgraded.

CYPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +204.08%▲ ASCENDING CHANNEL
2026-11-02O $3.24H $3.31L $2.98C $2.98VOL 18.78M
RES: $4.96SUP: $0.77SMA50: $2.78SMA200: $1.29
$4.45$3.38$2.30$1.23$0.16RES $4.96SUP $0.77$2.982026-05-042026-06-172026-08-042026-09-172026-11-02
CYPH // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE
UNDERWEIGHT CONVICTION: 28/100
BEAR 0
100 BULL

Cypherpunk Technologies Inc. (CYPH) exhibits 45.0% gross margins and -23.3% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 71.3x enterprise multiple and 4.8% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)
01. Operating Leverage & Capital Efficiency Moat

Sustained 45.0% gross profitability converts into — operating margin and -23.3% ROIC, outpacing sector cost of capital.

ROIC: -23.3% // GM: 45.0%
02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of — paired with -12.31% free cash flow yield supports self-funded R&D and capital return.

REV YOY: — // FCF YLD: -12.31%
03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 3.80 and Piotroski F-Score of 3/9 indicate low near-term refinancing stress.

ALTMAN Z: 3.80 // F-SCORE: 3/9
▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)
01. Multiple Compression & Duration Sensitivity

Trading at 71.3x trailing P/E (66.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 71.3x // EV/EBITDA: —
02. Options Skew & Event Volatility Risk

Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $2.98 max pain.

IMPL MOVE: ±5.2% // P/C: 0.85
03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend — net margins.

NET MARGIN: — // D/E: 0.45x
KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 66.3x forward consensus, and institutional 13F positioning.
MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.10).
FORM 4 & 13F FLOW OPEN OWN <GO>
FILER SIDE $ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>
UNUSUAL OPTIONS TAPE OPEN OPT <GO>
STRIKE / EXP TYPE PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>
KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>
TRAILING P/E 71.3x
FORWARD P/E 66.3x
EV / EBITDA —
FCF YIELD -12.31%
GROSS MARGIN —
OPERATING MARGIN —
NET MARGIN —
ROIC % -23.3%
REV GROWTH YOY —
DILUTED EPS TTM $0.05
DEBT / EQUITY —
DIVIDEND YIELD 0.00%
RSI-14 MOMENTUM 56.0
5Y EQUITY BETA —
FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>
MACRO CORRELATION CALIBRATION ACTIVE BELOW.
FRED MACRO REGIME STRESS-TEST SIMULATOR // CYPHPEARSON R VARIANCE ENGINE
01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO
02 // POSITION NOTIONAL EXPOSURE
HEADLINE STRESS SCORE
75/100SEVERE DRAWDOWN PRESSURE
PRIMARY FACTOR EXPOSURE
DFII10 // -0.61 r
Latest: 2.08%
EST. DIRECTIONAL MOVE
-8.50%
Implied Px: $2.73
EST. DOLLAR VARIANCE
-$4,248
On $50,000 Notional
[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CYPH & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>